Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2012-02-16 Regulatory Filings
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Change in substantial holding 4 pages 94.2KB
Regulatory Filings
2012-02-16 English
Delivery of Further Positive Oxycodone Patch Trial Results 2 pages 48.9KB
Capital/Financing Update Classification · 90% confidence The document is a company announcement dated 15 February 2012, reporting positive clinical trial results for a new oxycodone patch developed by Phosphagenics. It discusses trial design, results, and future plans including regulatory engagement and Phase 3 trials. The content focuses on product development and clinical trial outcomes rather than financial results or regulatory filings. It is not an earnings release, annual report, or regulatory filing. It is also not a presentation or a management discussion. The document is a press release announcing clinical trial results, which fits best under Capital/Financing Update (CAP) as it relates to development progress that could impact company valuation and financing, rather than other categories like legal, governance, or shareholder voting. The document length is under 5,000 characters and is a standalone announcement, not a report publication notice or certification. Therefore, the best classification is CAP with high confidence.
2012-02-14 English
Substantial Shareholding Notices - Form 605 and Form 604 7 pages 1.3MB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Company Announcement' and specifically mentions 'Substantial Shareholder Notices' with references to Form 604 and Form 605, which are standard forms for notifying changes in substantial shareholdings. The content discusses percentage dilution due to an increase in shares issued, and the cessation of substantial shareholder status for one party. There is no financial data, earnings information, or management discussion. The document is short (2018 characters) and is an announcement of shareholder notifications rather than a detailed report. Therefore, it fits the category of Major Shareholding Notification (MRQ).
2012-01-31 English
Change in substantial holding 4 pages 96.3KB
Regulatory Filings
2011-12-15 English
December 2011 eNewsletter and Placement of Shares 12 pages 1.8MB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Phosphagenics Limited dated December 2011. It contains a newsletter section and an equity raising update. The newsletter discusses company achievements, product development, clinical trials, commercial activities, and international launches. The equity raising section details the issuance of new shares following shareholder approval and completion of a $27.1 million capital raising. The document is lengthy (15,000 characters) and includes detailed information about the capital raising and company operations, not just a brief announcement or a link to a report. The primary focus is on the equity raising and company updates rather than a full annual or quarterly financial report. Therefore, the document fits best into the category of Capital/Financing Update (CAP), as it provides substantive information about fundraising activities and capital structure changes.
2011-12-13 English
Equity Raising correction re issue price 1 page 41
Capital/Financing Update Classification · 95% confidence The document is a company announcement correcting a previously stated issue price for a share equity raising. It clarifies the correct price per share and the total amount received from the share issue. The document is short (1521 characters) and focuses on a correction related to a capital raising event. There are no financial statements or detailed financial data, only an update on the share issue price. This fits the definition of a Capital/Financing Update (CAP) rather than a full report or announcement of a report publication. Therefore, the appropriate classification is CAP.
2011-12-13 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.